Lung Cancer Clinical Trial
IDO Peptid Vaccination in Combination With Immune Stimulating Agent Aldara and the Adjuvant Montanide, for Treatment of Patients With Locally Advanced or Metastatic Non Small-cell Lung Cancer. A First-in-man Phase I Trial.
|Start date||June 2010|
|Completion date||August 2012|
Title: IDO peptid vaccination in combination with immune stimulating agent Aldara and the
adjuvant Montanide, for treatment of patients with locally advanced or metastatic non
small-cell lung cancer. A first-in-man phase I trial.
Hypothesis: In this trial the investigators assess a new immunotherapeutic strategy targeting the immune inhibiting enzyme, IDO to investigate the potential of vaccination against IDO as a possible anticancer target.
Background: Non small-cell lung cancer (NSCLC) is a common disease with a poor prognosis
when locally advanced or metastasized, despite advances in surgery, chemo- and radiation
In this trial the investigators assess a new immunotherapeutic strategy targeting the immune inhibiting enzyme, IDO to investigate the potential of vaccination against IDO as a possible anticancer target.
IDO has recently been recognized as an important factor in immune regulation and development of immune tolerance in the microenvironment of cancer cells. Cells that represent IDO at their surface are known to inhibit the immune system. IDO expression is seen both in cancer cells and antigen presenting cells. The vaccination against IDO expressing cells is therefore two-sided. The vaccination therapy is thought to block the development of immune tolerance induced by IDO expressing cells. At the same time the investigators aim to stimulate the production of IDO specific T-cells, hence facilitating the elimination of IDO positive tumour cells. The primary end points are safety and toxicity evaluation. Secondary end points are immunological and clinical response.
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
|Recruiting||NCT02869217 - Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors||Phase 1|
|Recruiting||NCT02939729 - Physiotherapy Prehabilitation in Patients Undergoing Cardiac or Thoracic Surgery||N/A|
|Recruiting||NCT02869789 - A Safety Study of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers||Phase 3|
|Not yet recruiting||NCT02795923 - Nivolumab Alone or in Combination With Decitabine/Tetrahydrouridine in Non-small Cell Lung Cancer||Phase 2|
|Not yet recruiting||NCT02872701 - OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules||Phase 2|
|Recruiting||NCT02474355 - Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC||Phase 3|
|Recruiting||NCT02538666 - A Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy||Phase 3|
|Recruiting||NCT02444741 - MK-3475 and Hypofractionated Stereotactic Radiation Therapy in Patients With Non-Small Cell Lung Cancer (NSCLC)||Phase 1/Phase 2|
|Recruiting||NCT02558101 - Lung Screen Uptake Trial||N/A|
|Recruiting||NCT02513563 - AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer||Phase 2|
|Recruiting||NCT02565017 - Examining Patient Preferences About the IBM Watson Oncology Clinical Decision Support System||N/A|
|Recruiting||NCT02507778 - Circulating Tumor Cells Spillage After Pulmonary Biopsy||N/A|
|Recruiting||NCT02308709 - Novel Lung Functional Imaging for Personalized Radiotherapy||Phase 1|
|Recruiting||NCT02196844 - Yoga Program for Lung Cancer Patients and Caregivers||N/A|
|Recruiting||NCT02115464 - Advanced Lung Cancer Treatment With Metformin and Chemo-Radiotherapy||Phase 2|
|Completed||NCT02106143 - RejuvenAir™ System Lobectomy Safety and Histology Study||Phase 1|
|Completed||NCT02233842 - Cognitive Testing of Tobacco Use Measurement Items for Administration With Cancer Patients and Survivors||N/A|
|Recruiting||NCT01972386 - EBUS/Spectrum Analysis||N/A|
|Recruiting||NCT01852838 - The Contribution of Induced Glycolysis to the Exhaled Volatile Organic Compounds' (VOCs) Signature in Lung Cancer||N/A|
|Recruiting||NCT02017509 - Immunoscore in Rectal Cancer||N/A|